SCHEMBL7674074

SCHEMBL7674074

CCc1cc[c]c(CCc2ccc(OC)c(OC)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.50
ATM Q13315 2/20 0.49
KDM4E B2RXH2 1/20 0.49
POLB P06746 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CA2 P00918 1/20 0.46
BLM P54132 1/20 0.45
PMP22 Q01453 1/20 0.45
CALM1 P0DP23 2/20 0.44
AOC3 Q16853 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
STAT3 P40763 1/20 0.43
ABCB1 P08183 1/20 0.43
MAPT P10636 1/20 0.42
DAO P14920 1/20 0.42
HSP90AA1 P07900 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7671780 0.82 TUBB4A (0.45) CYP19A1KDM4ECALM1AOC3DAO
SCHEMBL7690876 0.80 CYP1A2 (0.51) CYP19A1ATMKDM4EPOLBCYP1A2
SCHEMBL31428 0.79 CA2 (0.71) CYP19A1ATMKDM4EPOLBCYP1A2
SCHEMBL31275634 0.79 CA2 (0.71) CYP19A1ATMKDM4EPOLBCYP1A2
SCHEMBL1776797 0.77 TRPA1 (0.34) CYP1A2
Ammonia Solution, Strong SCHEMBL266403 0.77 CA2 (0.68) CYP19A1ATMKDM4EPOLBCYP1A2
Water SCHEMBL8587595 0.77 CA2 (0.68) CYP19A1ATMKDM4EPOLBCYP1A2
SCHEMBL16641094 0.77 CYP19A1 (0.77) CYP19A1ATMKDM4EPOLBCYP1A2
SCHEMBL31157848 0.77 CYP19A1 (0.77) CYP19A1ATMKDM4EPOLBCYP1A2
SCHEMBL7668663 0.76 TAAR1 (0.38) CYP1A2DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6395730-B1 CARDIOVASCULAR DISORDERS ICAGEN, INC. 2002-05-28 US disclosed
US-6174908-B1 TREATING DISEASE, CONDITION, OR DISORDER WHICH RESPONDS TO INHIBITION OF POTASSIUM CHANNEL FUNCTION BY ADMINISTERING THIAZOLIDONE OR METATHIAZONONE COMPOUND, ITS SALT, AMIDE, ESTER, COMPLEX, CHELATE, HYDRATE, STEREOISOMER, METABOLITE ICAGEN, INC. 2001-01-16 US disclosed